The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 01, 2025

Filed:

May. 31, 2024
Applicant:

Visterra, Inc., Waltham, MA (US);

Inventors:

Karthik Viswanathan, Waltham, MA (US);

Brian Booth, Waltham, MA (US);

Boopathy Ramakrishnan, Waltham, MA (US);

Andrew Wollacott, Waltham, MA (US);

Gregory Babcock, Waltham, MA (US);

Zachary Shriver, Waltham, MA (US);

Lauren Olinski, Waltham, MA (US);

Assignee:

Visterra, Inc., Waltham, MA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 37/02 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2896 (2013.01); A61P 37/02 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.


Find Patent Forward Citations

Loading…